ARVN
Arvinas Inc
Chart
Stats
Earnings
News
Splits
Dividends
Earnings
| Actual EPS |
|---|
| Consensus EPS |
| Estimated EPS |
| Number of Estimates |
| EPS Surprise |
Stats
Summary
arvinas is a pharmaceutical company focused on developing new small molecules ‒ known as protacs (proteolysis targeting chimeras) ‒ aimed at degrading disease-causing cellular proteins via proteolysis. based on innovative research conducted at yale university by dr. craig crews, founder and chief scientific advisor, the company is translating natural protein degradation approaches into novel drugs for the treatment of cancer and other diseases. the proprietary protac-based drug paradigm induces protein degradation, rather than protein inhibition, using the ubiquitin proteasome system and offers the advantage of potentially targeting “undruggable” as well as “druggable” elements of the proteome. this greatly expands the ability to create drugs for many new, previously unapproachable targets. for more information, visit www.arvinas.com.
Market Cap: 3.13 Billion
Primary Exchange: NASDAQ
Website: arvinas.com
Shares Outstanding: 68.1 Million
Float: 0
Dividend: 0.0 (0.0%)
Beta: 1.8267867740947081
Sector: Manufacturing
Industry: Medicinal and Botanical Manufacturing
Ethical Flags
Longest drawdown: 852 trading days
From: 2021-07-29 To: 2024-03-07
Lowest Point:
Arvinas (ARVN) Investor Presentation - Slideshow
via: SeekingAlpha at 2019-06-12 11:14:17:000
The following slide deck was published by Arvinas, Inc. in conjunction with this Read more … read more...
Arvinas (ARVN) Investor Presentation - Slideshow
via: SeekingAlpha at 2019-06-12 11:14:17:000
The following slide deck was published by Arvinas, Inc. in conjunction with this Read more … read more...
| Ex-Date | Payment Date | Record Date | Declared Date | Amount | Flag | Dividend Type | Qualified | Indicated |
|---|
| Ex-Date | Declared Date | Record Date | Payment Date | Ratio | To Factor | For Factor |
|---|